All-Cause Costs Increase Exponentially with Increased Chronic Kidney Disease StageByLadan Golestaneh, MD, MS,Paula J. Alvarez, RPh, MPH, MBA,Nancy L. Reaven, MA,Susan E. Funk, MBA, FACHE,Karen J. McGaughey, PhD,Alain Romero, PhD,Melanie S. Brenner, PharmD, BCPS,Macaulay Onuigbo, MD, MSc, MBAJune 21st 2017
Evaluation of Clinical Outcomes and Costs Based on Prescribed Dose Level of Renin-Angiotensin-Aldosterone System InhibitorsByMurray Epstein, MD,Paula J. Alvarez, RPh, MPH, MBA,Nancy L. Reaven, MA,Susan E. Funk, MBA, FACHE,Karen J. McGaughey, PhD,Melanie S. Brenner, PharmD, BCPS,Wade Benton, PharmD,Ladan GolestaneAugust 31st 2016
